Study Confirms Regulatory-Grade Performance and AI-Driven Clinical Utility to Advance Precision Oncology and Patient Stratification for Drug Development BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced the publication of a pivotal study, “Clinical and analytical validation of a combined RNA and DNA exome assay across a large tumor cohort,” in Communications…
Techcyte, a leading provider of AI-powered digital diagnostics for anatomic and clinical pathology, today announced that its platform, Techcyte Fusion (research use only (RUO) in the US, CE-IVDD-marked in Europe), now includes Modella AI, a biomedical artificial intelligence company at the forefront of computational pathology, as a partner in the Techcyte Fusion Partner Program. This collaboration brings…
Integration of Direct Secure Messaging and Intelligent Document Processing benefits healthcare organizations with faster access to structured data to support care delivery and interoperability Concord Technologies (“Concord”), a leader in Secure Document Exchange, Intelligent Document Processing, and Interoperability solutions, today announced the upcoming launch of Direct Secure Messaging (DSM) within its Concord Connect platform, available…
Dental AI leader trusted by over 50,000 dental professionals, recognized for rapid growth and transformative impact on the industry VideaHealth, the dental AI platform trusted by 8 of the 10 largest DSOs in North America and over 50,000 dental professionals, today announced it has been ranked No. 28 on the Inc. 5000 list, the nation’s…
This Marks SamaCare’s Second Time on the List, Ranking in the top 12% of America’s Fastest-Growing Companies Inc., the leading media brand and playbook for the entrepreneurs and business leaders shaping our future, today announced that SamaCare, a cloud-based patient access platform for specialty medications, is No. 578 on the annual Inc. 5000 list, the most prestigious…
Claritas NucMed Technologies Ltd (Claritas), a healthcare technology company specializing in state-of-the-art signal processing, quantification and AI technologies for the nuclear medicine industry, is pleased to announce that iPETcertum, a software device for enhancement, automated segmentation and quantification in PET (Positron Emission Tomography) scans has received FDA clearance. The iPETcertum segmentation feature enables clinicians to visualize, on…
Prestigious International Annual Awards Program Honors Standout AI Companies & Solutions BostonGene, a leader in AI-powered solutions for drug discovery and development, has been honored with the “AI-based Drug Discovery Solution of the Year” award in the 8th annual AI Breakthrough Awards program. AI Breakthrough is a leading market intelligence organization that recognizes the top companies, technologies and…
One billion cells to power the next generation of AI models in biology Tahoe Therapeutics today announced $30 million in new funding to build the definitive foundational dataset for training Virtual Cell Models. With this, the team will generate one billion single-cell datapoints, mapping one million drug-patient interactions, a scale previously impossible. The dataset will support…
Funds will support advancement of Tevogen.AI, the Company’s artificial intelligence–driven drug discovery initiative. The $1 million is part of up to $10 million in previously announced non-dilutive grant funding from KRHP LLC. The Company remains well-capitalized, enabling it to fully execute its growth strategy. Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced it…
Fullpower-AI®, a leader in AI-powered health and wellness technologies, today announced a transformative partnership with Tempur Sealy International (“Tempur Sealy”), a wholly-owned business of Somnigroup International Inc., anchored by a 10-year global licensing agreement for Fullpower-AI’s KOA Sleeptracker-AI Large Action Model (LAM) platform. As part of the agreement, Tempur Sealy will make a $25 million Series C investment in Fullpower-AI, valuing…